Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-04-24

Clinical Trial Update: A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight [Phase 3]

View source ↗

Summary

Phase 3 trial of Survodutide (BI 456906) in overweight or obese adults with Type 2 diabetes has completed, with an update on the study status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Survodutide (BI456906)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Obesity, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED